Shares of Natera Inc (NASDAQ:NTRA) have been given an average rating of “Buy” by the eight brokerages that are presently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $42.40.

A number of brokerages recently commented on NTRA. JPMorgan Chase & Co. upped their price target on shares of Natera from $27.00 to $32.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. Cowen lifted their price objective on shares of Natera from $30.00 to $42.00 and gave the stock an “average” rating in a report on Friday, October 18th. ValuEngine lowered Natera from a “buy” rating to a “hold” rating in a research note on Tuesday. Canaccord Genuity reiterated a “buy” rating and issued a $44.00 price objective on shares of Natera in a report on Wednesday, October 16th. Finally, Zacks Investment Research lowered Natera from a “buy” rating to a “hold” rating in a research report on Tuesday, November 12th.

In related news, CFO Michael Burkes Brophy sold 2,859 shares of the firm’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $37.50, for a total transaction of $107,212.50. Following the completion of the transaction, the chief financial officer now directly owns 16,630 shares of the company’s stock, valued at $623,625. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CTO Jonathan Sheena sold 1,033 shares of Natera stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $29.50, for a total transaction of $30,473.50. Following the completion of the sale, the chief technology officer now owns 241,937 shares in the company, valued at $7,137,141.50. The disclosure for this sale can be found here. Insiders have sold 63,854 shares of company stock valued at $2,231,769 in the last quarter. 9.29% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC purchased a new stake in shares of Natera in the third quarter worth about $36,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Natera by 23.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,837 shares of the medical research company’s stock worth $93,000 after buying an additional 537 shares in the last quarter. US Bancorp DE increased its position in shares of Natera by 575.2% during the second quarter. US Bancorp DE now owns 3,099 shares of the medical research company’s stock worth $86,000 after purchasing an additional 2,640 shares in the last quarter. Bank of Montreal Can acquired a new position in Natera in the 2nd quarter valued at $129,000. Finally, Hershey Trust Co. acquired a new position in Natera in the 3rd quarter valued at $194,000. Hedge funds and other institutional investors own 84.90% of the company’s stock.

NASDAQ NTRA traded up $0.70 during trading on Friday, hitting $36.86. 31,140 shares of the company’s stock traded hands, compared to its average volume of 681,662. The stock has a market capitalization of $2.83 billion, a price-to-earnings ratio of -17.15 and a beta of 1.40. Natera has a 12-month low of $11.08 and a 12-month high of $40.92. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.26 and a current ratio of 2.35. The business has a 50 day moving average of $38.07 and a 200-day moving average of $31.00.

Natera (NASDAQ:NTRA) last posted its earnings results on Wednesday, November 6th. The medical research company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.20. Natera had a negative net margin of 42.45% and a negative return on equity of 252.79%. The firm had revenue of $77.90 million during the quarter, compared to the consensus estimate of $73.97 million. During the same quarter last year, the company earned ($0.49) earnings per share. The company’s revenue was up 19.3% on a year-over-year basis. On average, analysts expect that Natera will post -2.15 EPS for the current year.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: How To Calculate Debt-to-Equity Ratio

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.